Firebrick Pharma (ASX:FRE) removed a competitor product to its Nasodine nasal spray from the Singapore market for a violation of its patent, according to a Tuesday filing with the Australian bourse.
The firm said it became aware that Medzolution, a company in Singapore, was offering a nasal spray containing povidone-iodine for sale online. It considers the promotion and sale of this nasal spray an infringement of its Singapore patent, which covers the use of a povidone-iodine nasal spray as a treatment and preventative for the common cold.
The firm received a signed undertaking from Medzolution acknowledging the validity of its patent and Medzolution will withdraw its nasal spray from the market as well as stop all marketing and advertising of the product in Singapore.
Medzolution will also deliver the full stock of the nasal spray in its possession to Firebrick's legal representatives in Singapore.
Medzolution also consented to an injunction against its actions in case of a breach of the undertaking and it will indemnify Firebrick against any legal costs involved in Firebrick's enforcing the undertaking.
The firm is in the process of launching Nasodine in Singapore through an exclusive arrangement with the Guardian pharmacy group, its Executive Chairman, Peter Molloy said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。